Učitavanje...
Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations
Gastric and esophageal cancers represent a major global cancer burden and novel approaches are needed. Despite recent improvements in outcomes with trastuzumab and ramucirumab the prognosis for advanced disease remains poor, with a median overall survival of 1 year. Comprehensive genomic characteriz...
Spremljeno u:
| Izdano u: | J Gastrointest Oncol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AME Publishing Company
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4570917/ https://ncbi.nlm.nih.gov/pubmed/26487950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2015.037 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|